Effect of ticagrelor on clinical efficacy, coagulation function and platelet aggregation in patients with coronary heart disease undergoing interventional therapy / 中国基层医药

ABSTRACT

Objective@#To study the effects of ticagrelor on clinical efficacy, coagulation function and platelet aggregation in patients with coronary heart disease.@*Methods@#From January 2017 to December 2017, 78 patients in the Department of Cardiology of the First People's Hospital of Huzhou were randomly selected in this study.All patients were treated with interventional therapy.According to the different drug used in the interventional therapy, the patients were divided into the observation group and the control group, with 39 cases in each group.The patients in the control group were given clopidogrel during interventional therapy, and the patients in the observation group were given ticagrelor during interventional therapy.The coagulation function and platelet aggregation rate of the patients before and after treatment were observed, and the clinical efficacy and satisfaction rate of the patients were observed.@*Results@#After treatment, the prothrombin time, activated partial thromboplastin time, thrombin time and fibrinogen level were (12.48±1.01)s, (31.91±2.53)s, (17.06±1.03)s and (4.21±1.09)μg/L, respectively, which were significantly better than those in the control group(t=18.980, 17.092, 15.993, 11.762, all P<0.05). The total effective rate and satisfaction rate of the observation group were 89.745% and 97.44%, respectively, which were significantly higher than those of the control group, and the differences were statisticall significant(χ2=9.983, 8.973, all P<0.05).@*Conclusion@#The clinical efficacy of ticagrelor in the interventional treatment of coronary heart disease is significant, which can significantly improve the coagulation function.